Teneobio
Latest round
- Series A
Last raised
- Dec 2016
Total raised
- $34M
Investors
- 2
About Teneobio
Based in California, US, Teneobio, Inc. operates as a biotechnology company that engages in the development of biologics for the treatments of cancer, autoimmunity, and infectious diseases. In October 2021, Amgen Inc. acquired Teneobio, Inc.6 billion. Teneobio specializes in the development of bispecific and multispecific, heavy-chain antibody technologies to redirect the immune system to fight disease. Its notable contributions include advanced T cell engagers and proprietary antibody platforms. The company’s key asset was TNB-585, a Phase 1 bispecific T cell engager aimed at treating metastatic castrate-resistant prostate cancer, alongside several promising preclinical oncology assets.
Who invested in Teneobio
2 investors across 1 round
See all investors in Teneobio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 31, 2016
Amount
$34M
Investors
Questions about Teneobio
Who invested in Teneobio?
Teneobio has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Teneobio raised?
Teneobio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Teneobio last raise money?
Teneobio's most recent round on record is a Series A, in Dec 2016.
What does Teneobio do?
Based in California, US, Teneobio, Inc.
Where is Teneobio headquartered?
Teneobio is headquartered in Newark, US.
Which VCs invest in companies like Teneobio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Teneobio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Teneobio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.